BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned

Dickon Hayne; Martin Stockler; Steve P McCombie; Nicola Lawrence; Andrew Martin; Shomik Sengupta; Ian D Davis

doi:10.1111/bju.13873

BCG + Mitomycin trial for high-risk non-muscle-invasive bladder cancer: progress report and lessons learned

BJU Int. 2017 May:119 Suppl 5:55-57. doi: 10.1111/bju.13873.

Authors

Dickon Hayne^{1

2

3}, Martin Stockler^{1

4}, Steve P McCombie^{1

3}, Nicola Lawrence^{1

4}, Andrew Martin^{1

4}, Shomik Sengupta^{1

5

6

7}, Ian D Davis^{1

8}

Affiliations

¹ Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Camperdown, NSW, Australia.
² University of Western Australia Medical School, Crawley, WA, Australia.
³ Fiona Stanley Hospital Urology, Murdoch, WA, Australia.
⁴ NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
⁵ Department of Urology, Austin Health, Melbourne, Vic., Australia.
⁶ Austin Department of Surgery, University of Melbourne, Melbourne, Vic., Australia.
⁷ Ludwig Institute for Cancer Research, Austin Hospital, Melbourne, Vic., Australia.
⁸ Monash University Eastern Health Clinical School, Box Hill, Vic., Australia.

PMID: 28391606
DOI: 10.1111/bju.13873

No abstract available

Publication types

Letter
Meta-Analysis
Research Support, Non-U.S. Gov't
Review

MeSH terms

Administration, Intravesical
Australia
BCG Vaccine / administration & dosage*
Clinical Trials, Phase III as Topic
Disease-Free Survival
Female
Humans
Male
Mitomycin / administration & dosage*
Neoplasm Invasiveness / pathology
Neoplasm Staging
Prognosis
Randomized Controlled Trials as Topic
Risk Assessment
Survival Analysis
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / mortality
Urinary Bladder Neoplasms / pathology*

Substances

BCG Vaccine
Mitomycin